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Summary L-Glutamate (Glu) plays a crucial role in the
growth of malignant gliomas. We have established the fea-
sibility of accelerating a naturally occurring brain to-blood
Glu efflux by decreasing blood Glu levels with intravenous
oxaloacetate, the respective Glu co-substrate of the blood
resident enzyme humane glutamate–oxaloacetate transami-
nase (hGOT). We wished to demonstrate that blood Glu
scavenging provides neuroprotection in the case of glioma.
We now describe the neuroprotective effects of blood Glu
scavenging in a fatal condition such as brain-implanted C6
glioma in rats and brain-implanted human U87 MG glioma
in nude mice. Rat (C-6) or human (U87) glioma cells were
grafted stereotactically in the brain of rats or mice. After
development of tumors, the animals were drinking oxaloac-
etate with or without injections of hGOT. In addition, mice
were treated with combination treatment, which included
drinking oxaloacetate with intracutaneous injections of
hGOT and intraperitoneal injection of Temozolomide. Ani-
mals drinking oxaloacetate with or without injections of
hGOT displayed a smaller tumor volume, reduced invasive-
ness and prolonged survival than control animals drinking
saline. These effects were significantly enhanced by Temo-
zolomide in mice, which increased survival by 237%. This
is the first demonstration of blood Glu scavenging in brain
cancer, and because of its safety, is likely to be of clinical
significance for the future treatment of human gliomas. As
we demonstrated, the blood glutamate scavenging treatment
in combination with TMZ could be a good candidate or as
an alternative treatment to the patients that do not respond to
TMZ.
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Introduction
In the last few years, an ever increasing body of data have
suggested that L-Glutamate (Glu) plays a crucial role in the
growth of malignant gliomas, their invasiveness and ability
to destroy neighboring brain tissue while being also the
possible cause of the tumor-associated seizures that often
occur in conjunction with gliomas [1–4].
Studies with glioma cells in culture have shown that the
cells release massive amounts of Glu resulting in elevations
of the extracellular concentrations of Glu in excess of
100 μM within hours in a space that is 1,000-fold larger
than the cellular volume [5]. Significant increases were also
demonstrated in the peritumoral space surrounding experi-
mental brain tumors in rats [6] and in malignant gliomas and
oligodendrogliomas in human patients [7, 8]. Glu release
occurs via system X(c), a Glu-cystine exchanger that
releases Glu in exchange for cystine [9], which is used for
the synthesis of the cellular antioxidant glutathione. The
latter protects tumor cells from endogenously produced
reactive oxygen and nitrogen species and also endows
tumors with an enhanced resistance to radiation and
chemotherapy.
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In addition to the role of Glu-cystine exchanger, antago-
nists of the NMDA and AMPA receptors, two major sub-
types of Glu receptors, have been found to inhibit the
proliferation and migration of both rat [10] and human
[11] malignant gliomas while an antagonist of the Glu
metabotropic receptor inhibits Glu release from glioma cells
and prevents neurotoxicity [12].
Since gliomas appear to co-opt Glu, its exchangers and
receptors [11] in support of their invasive migration, they
can be added to the long list of neurological diseases in
which Glu excitotoxicity is the common destructive path-
way. Accordingly, the therapeutic strategies that have been
proposed to counteract the Glu-supporting effects on glioma
invasiveness which are based on the use of Glu release
inhibitors and Glu receptor antagonists [11, 13, 14] are
precisely the same as those proposed for the treatment of
acute neurodegenerative disorders involving excess Glu in
brain such as stroke or head trauma.
This might appear to be a very promising anti-tumor
therapeutic avenue to follow but for the fact that, though
very effective in preventing or limiting the neuronal degen-
erative process in animal models of ischemia and head
trauma, the Glu receptors antagonists were found to produce
unacceptable side effects or even lethal effects in human
clinical trials [15].
The alternative therapeutic strategy based on blood Glu
scavenging that is proposed here offers a new and safe
avenue for coping with the excess peritumoral Glu and its
deleterious effects.
Blood Glu scavenging as a neuroprotective therapy
The maintenance of brain extracellular Glu at levels below
its excitotoxic threshold is performed not only by the Glu
transporters located on glia and neurons but also by those
present on the antiluminal side of the brain capillary endo-
thelial cells [16, 17]. These transporters remove the excess
extracellular brain Glu into blood [18, 19].
We have established [19] the feasibility of accelerating
this naturally occurring brain to-blood Glu efflux by de-
creasing blood Glu levels with intravenous oxaloacetate
(OxAc) or pyruvate, the respective Glu co-substrates of the
blood resident enzymes glutamate–oxaloacetate transami-
nase (GOT) and glutamate–pyruvate transaminase (GPT).
We later demonstrated that blood Glu scavenging provides
highly significant brain neuroprotection since both OxAc
and pyruvate improve the neurological status of rats submit-
ted to close head injury [20–22].
The latter papers lacked the direct evidence that blood
Glu scavenging is the direct cause of a decrease of Glu in the
brain fluids in areas where it is in excess. The evidence for
that, was recently provided for the first time by a very recent
paper of Campos et al., 2011 [23]. In an animal model of
middle cerebral arterial occlusion (MCAO) following the
Stroke Therapy Academic Industry Roundtable (STAIR)
group guidelines [24], oxaloacetate-mediated GOT activa-
tion was found to inhibit the increase of blood and cerebral
Glu, to reduce the infarct size, the edema volume, and lower
sensorimotor deficits with respect to controls. Magnetic
resonance spectroscopy established that the excess of Glu
levels in the infracted brain parenchyma decreased in paral-
lel with the decrease of blood Glu levels [23].
In two clinical independent studies including more than
350 stroke patients, Campos et al. 2011 [25] found that
patients with poor outcome and larger infarct volume at
three months of hospitalization show higher Glu [26] and
lower GOT levels in blood at the time of hospital admission
as compared to those patients with good outcome that had
higher blood GOT levels. These findings of Campos et al.
(2011) not only bring the final missing proofs for the neuro-
protective mechanism of blood Glu scavenging, but also
suggest that a treatment to increase GOT levels and decrease
Glu in blood, will show effectiveness for neuroprotection in
brain pathologies where Glu is in excess.
Blood Glu scavenging as a chronic therapy
So far, the optimal blood Glu scavenging treatment for the
acute neurodegenerative conditions has consisted of a
30 min long intravenous administration of OxAc and re-
combinant GOT. This combination is required both for the
administration of realistic concentrations of OxAc and for
the fact that the basal GOT levels in blood are limiting [22].
In our previous studies, we intravenously injected rats with
OxAc to reach a steady state concentration in blood [19].
However, one can maintain (as expected from the
Michaelis-Menten equation) the same rate of blood Glu
transamination by reducing significantly the concentration
of the administered OxAc while increasing in parallel the
GOT blood concentration. Using this approach, we found
[22] that an optimal blood Glu scavenging and neuropro-
tection after TBI could be attained by administering 1 ml of
10 mM OxAc/100 g rat (this dose is ineffective on its own)
together with 13 μg recombinant GOT. Increasing the GOT
concentration in blood facilitates the OxAc-mediated blood
Glu scavenging since it allows the intravenously adminis-
tered OxAc to readily react with the transaminase before
being transported into the various body organs via the
dicarboxylate transporters [27, 28].
For studying a chronic disease such as glioma, we relied on
the endogenous blood levels of GOT for OxAc-mediated
blood Glu scavenging and the treatment modality we used
was based on restricting the rats to a drink of 0.2 M OxAc in
tap water. The above oral treatment probably should be mod-
ified for the clinical trials since OxAc is subjected to a first-
pass metabolism in the liver as well as an absorption into the
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gut wall on its possible way to the portal vein. Accordingly,
the plausible mechanism for blood Glu scavenging could be
based on a GOT-mediated transamination reaction taking
place not only in blood but also in the liver leading to a
reduced Glu output from the liver into blood [29].
In the present study we investigated whether blood Glu
scavenging could be used in experimental glioma to reduce
the brain levels of excess Glu that are continuously released
by the tumor cells. Our results demonstrate the therapeutic
effects of blood Glu scavenging in a C6 glioma rat model as
well as in the human U87 MG glioma model in nude mice.
Materials and methods
Materials
Rat C6 glioma and human U-87 Glioma cells were obtained
from ATCC. The tumor cell lines were routinely tested for
authenticity by microsatellite analysis, at the ATCC. Oxalo-
acetic acid was obtained from Sigma. His-tagged human
Glutamate-Oxaloacetate transaminase (hGOT) cDNA was
cloned from the human hepatoma cell line hepG2, expressed
in E. coli and purified by Ni-agarose chromatography.
Temozolomide was obtained from Schering Corporation.
A stock solution of temozolomide (12.5 mg/ml) was pre-
pared in 100% DMSO, and then filtered through a 0.22 μm
filter. 1 ml aliquots were placed in sterile Eppendorf tubes
and stored at −70°C. Immediately prior to injection, the
stock drug solution was thawed, diluted in sterile saline to
a final concentration of 0.125 mg/ml. 5 mg/kg Temozolo-
mide was injected intraperitoneally at day 7 post tumor
implantation in a volume of 1 ml saline/ 1% DMSO (Temo-
zolomide dose: 15 mg/m2 and 120 ml/m2).
Animals
The experiments were conducted according to the recommen-
dations of the declarations of Helsinki and Tokyo and to the
Guidelines for the Use of Experimental Animals of the Euro-
pean Community approved by the Animal Care Committees
of Weizmann Institute of Science. The experiments with C6
glioma were carried out on male rats of the Sprague–Dawley
strain, weighing 250–300 g (Harlan Biotech, Israel). The
experiments with U87 MG were carried out in male CD1
nude mice, 9–10 weeks (Harlan Biotech, Israel). Purina Chow
and water were available ad libitum. Ambient temperature
was set to 22–23°C.
Intracerebral injections of C6-glioma
Rats were anesthetized with 1.5% Halothane (Rhodia) solu-
tion by a respiration system and immobilized on a stereotaxic
unit. After disinfection and incision of the skin, C6 cells were
stereotaxically implanted in the left anterior corpus striatum
using the following coordinates: 0 mm bregma, +3 mm left
lateral, and 5.5 mm depth. C6 cells were resuspended in PBS
(104 cells/2 μl) and implanted at an infusion rate of 1 μl/
10 min. The needle was left in place 5 min after cell infusion
and it was slowly withdrawn. All tumor cell implantations
were performed using a Hamilton syringe with a 26-gauge
needle (Hamilton Co.) attached to the stereotaxic system.
Seven days after the tumor cell implantation, rats were
randomly divided into two therapeutic groups (n014 for
control group and n015 for treated group). The treated
group was provided daily with a freshly-prepared 0.2 M
OxAc solution in water. The pH was adjusted to 7.0–7.4
with 1 M NaOH. Since the OxAc solution included Na+
molecules originals from the neutralizing NaOH, the control
group was provided with NaCl (0.3 M) solution as their
drinking water. Rats were monitored daily to detect any
signs of neurological suffering from tumor growth or from
toxicity effects of the therapy. All the rats survived until the
end of the experiment and were sacrificed at day 21–22 post
tumor implantation (PID).
Magnetic resonance imaging
High resolution brain MRI was performed twice using T2 and
T1-weighted imaging before and after injection of 0.4 ml
contrast medium (Gadodiamide, Omniscan, Amersham) into
the tail vein. The animals were examined in a 4.7 Tesla
(200 MHz, 1 H) magnet with a 40 cm inner diameter bore
system (Bruker Biospec, Ettlingen, Germany). A birdcage
radiofrequency (RF) coil with an inner diameter of 70 mm
was used. In vivo multi-slice images of rat brains were ac-
quired in the coronal plane (ten slices; slice thickness 1.0 mm;
matrix0128×128, field of view032×32mm2).T2W images
were acquired using a fast-spin-echo sequence (echo train
length 0 4; repetition time 0 3 s; echo time 0 64 ms; number
of averages 0 2). T1w images (repetition time0700 ms; echo
time 0 10 ms; number of average 0 10) with and without
gadolinium enhancement were acquired with the same geom-
etry and location as the T2w image. Gadodiamide-enhanced
T1 imaging was performed 5 min after injection. During MRI
examination, rats were anesthetized by isoflurane (initial dose
2.5%, maintenance 1.6%). To assess the tumor size, rats were
submitted toMRI at day 7 PID. After 14 days of treatment (21
PID), rats were submitted again to MRI to establish the extent
of tumor growth estimated using serial T1-Wand T2-W spin-
echo sequence images evaluated with the Surf driver program.
Tumor volumes were determined using MRIcro software At 7
PID T1 and T2 imaging were performed as a volume of the
tumor was small and the borders were poorly detectable in the
T2 imaging. At 21 PID only T2 imaging was performed as a
2228 Invest New Drugs (2012) 30:2226–2235
volume of the tumor was big and the shorter anesthesia time
kept all the animals alive up to the end of the procedure.
U87 MG cell intracerebral implantation and treatment
Orthotopic glioblastoma-bearing mice were obtained by an
intracranial implantation of 25×105 U87 MG cells in 10-
weeks-old male immunodeficient CD1 nude mice under
xylazine (10 mg/kg)/ketamine (70 mg/kg), anesthesia. After
disinfection and incision of the skin, U87 cells were stereo-
taxically implanted using the following coordinates: 0.5 mm
forward from the bregma, 2.1 mm lateral, and 3.0 mm
ventral from the dura. Seven days after tumor cell implan-
tation, mice were randomly divided into five groups (n013/
group, totally 65 mice).
Group 1 was a control group of CD1 nude mice to which,
starting on day 7 post tumor implantation, a subcutaneous
administration of 200 μl saline was performed every other
day until death. Starting from day 7 and on four consecutive
days, mice were injected intraperitoneally with 1 ml PBS/
1% DMSO and until the termination of the experiment, mice
were supplied with drinking water containing of 0.3 M NaCl
in tap water.
Group 2 was a treatment group of mice to which, starting
on day 7 post tumor implantation, a priming dose of hGOT
2.14 mg/kg was administered subcutaneously in 200 μl saline
followed by maintenance doses of hGOT 0.214 mg/kg in
200 μl saline performed every other day until death. On day
7 and on four consecutive days, mice were injected intraper-
itoneally with 1 ml saline/1% DMSO. Starting on day 7, until
the termination of the experiment, mice were offered drinking
water consisting of 0.2 M OxAc in tap water.
Group 3 was a treatment group of mice to which TMZ
was administered. Starting on day 7 post tumor implanta-
tion, subcutaneous administrations of 200 μl saline were
performed every other day until death. Also, starting from
day 7 and on four consecutive days, mice were injected
intraperitoneally with 1 ml saline/1% DMSO containing
5 mg/kg of TMZ. Until the termination of the experiment,
mice were supplied with drinking water consisting of 0.3 M
NaCl in tap water.
Group 4 is a combination treatment with TMZ/OxAc/
hGOT. Starting on day 7 post tumor implantation, a priming
dose of hGOT 2.14 mg/kg was administered subcutaneously
in 200 μl saline followed by maintenance doses of
0.214 mg/kg in 200 μl saline performed every other day
until the termination of the experiment. On day 7 and on
four consecutive days, mice were injected intraperitoneally
with 1 ml saline/1% DMSO containing 5 mg/kg of TMZ.
Starting on day 7 and until death, mice were offered drink-
ing water consisting of 0.2 M OxAc in tap water.
Mice were monitored daily to detect any signs of neuro-
logical suffering from tumor growth or from toxicity effects
of the therapy. At day 14, the mice were deeply anesthetized
with urethane (1.3 g/kg, i.p.) and rapidly perfused trans-
cardially with 50 ml of 0.1 M phosphate buffer, (pH 7.4)
containing 4% paraformaldehyde (Sigma-Aldrich, Israel;
BioLab, Israel). Brains were removed and the hemisphere
containing the tumor, as well as the contralateral hemisphere
(for control), were postfixed in the same fixative overnight.
Tumor volume was estimated by histology analysis.
Histology and immunohistochemistry
At indicated time points, the animals were anesthetized and
perfused transcardially with chilled PBS, brains were re-
moved and fixed in Bouin fixative or in 4% formalin.
Samples were processed for paraffin embedding by standard
procedure. Coronal brain serial sections 6 μm thick were
generated with spacing 500 micron between series. All
sections which included glioma cells were used for histolo-
gy and immunohistochemistry. From each sectional level
four slides were generated. One of them was stained by
hematoxylin and eosin (H&E) and the adjacent three slides
were used for immunohistochemistry For immunostaining,
after deaxing and hydration of sections, antigen retrieval
was done in citrate buffer (pH 6.0) using a microwave
technique. Endogenous peroxidase was blocked and the
sections were incubated overnight with primary antibody
at 4°C. The PC-10 monoclonal antibody to proliferative
nuclear antigen ( PCNA) (BioLegend, San Diego,CA) di-
luted 1:1,000, a cocktail of mouse monoclonal antibody to
glial fibrillary acid protein (GFAP) (BD Bioscience) diluted
1:200 and goat anti Aurora Kinase A/AURKA antibody
diluted 1:50 (Sigma) were used. The antibody binding was
visualized using streptavidin-peroxidase complex Histofine
(Nichirei, Tokyo, Japan). Peroxidase activity was revealed
with 0.01% hydrogen peroxide, using 3,3′-diaminobenzi-
dine as the chromogen (Sigma). Known positive controls
and negative controls were included in each batch.
Quantitative evaluation
Sections were observed and captured through an optical
Eclipse E800 microscope (Nikon, Japan) and a digital camera
DMX 1200 (Nikon,Japan). ImagePro Plus software (Media
Cybernetics, Silver Spring, MD) was used for quantitative
analysis. Volume of tumor was estimated by three dimensional
reconstructions after tracing of tumor contour on the images of
H&E stained serial sections. The number of tumor cell nuclei
per 10,000 micron was calculated in 10 microscopic fields of
each sample (objective magnification ×40), allowing treat-
ment effects to be tested on tumor cellularity. Proliferative
activity in tumor tissue was evaluated on the slides stained for
PCNA by counting immune-positive nuclei and immune-
negative tumor cell nuclei in 10 microscopic fields of each
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sample (objective magnification ×40) and expressed as per-
cent of immune-positive nuclei to the total nuclei counted.
Astrocytes were identified by using GFAP immunohisto-
chemistry. The quantification of GFAP-positive cells was
performed on the images captured from the field of brain
tissue around the tumor by objective magnification ×40 for
assessment glial scar density around the tumor. At least five
images in each case were used for analysis. Number of stained
cells per area was used for assessment of glial scar density
around the tumor. All morphometric analyses were performed
without previous knowledge of the experimental group from
which the sections were obtained.
Survival assay
We repeated the therapy with intracranial U87 MG xeno-
grafted mice, comparing the four groups on a survival basis.
Orthotopic glioblastoma-bearing mice were obtained by an
intracranial implantation of 25×105 U87 MG cells in 10-
week-old male CD1 nude mice. Seven days after the tumor
cell implantation, mice were randomly divided into four
therapeutic groups (n013/group). Schedule and doses of
therapeutics were the same as mentioned above. Mice were
monitored daily and euthanized at the appearance of severe
neurological damage from tumor growth.
Statistics
Statistics were calculated using Prism version 4.0 (GraphPad
software). Student’s t-Test (two-tailed) was used to look for
significant differences between cell number in C6 cells ex-
posed to OxAc, MRI analysis of intrastriatal infusion of C6
cells and viability increase in U87 cells exposed to OxAc.
One-way ANOVAwith Newman-Keuls post test was used to
compare tumor growth in CD1 nude mice. Kaplan-Meier
survival graphs were analyzed by Log-rank test. In all tests,
statistical significance was assumed for p<0.05.
Results
The effect on tumor development following the chronic
administration of 0.2 M OxAc in the drinking solution of
C6-glioma implanted rats
In order to evaluate the potency of the oral treatment of
brain C6 glioma with a blood Glu scavenger such gas OxAc,
cultured C6 cells were implanted into the left striatum of rats
to induce tumors and the accompanying neovascularization.
The tumor development was followed by MRI. Seven days
after the cell implantation, as the presence of a growing
tumor mass was confirmed by MRI (Fig. 1a. left column),
the rats (n015) were offered a drink with a 0.2 M OxAc
solution as the oral solution while the control rats (n014)
were offered a liquid containing of 0.3 M NaCl. MRI
analysis shows that OxAc-treated rats significantly reduced
tumor growth as compared to the control group. (p<0.01,
repeated measures ANOVA, Fig. 1a. right column and b).
Blood glutamate scavenging in combination with TMZ
inhibits tumor growth in an orthotopic CD1 nude glioma
model
On the strength of the fact that the administration of exog-
enous GOT transforms an ineffective low dose of OxAc into
Fig. 1 a. A representative example of MRI analysis of C6 glioma
growth in vivo. At 7 days post-implantation and before the treatment,
an MRI imaging was performed (left column, 1–2 pictures T2 imaging,
3–4 pictures T1 imaging). The rats were randomized and either treated
with 0.2 M OxAc or 0.3 M NaCl for additional 14 days. The MRI
imaging was performed again at the end of the treatment (21 days post
glioma implantation, right column, 1–4 pictures T2 imaging). b. Tumor
volume of the rats before and after the treatment was calculated in n0
14 for control group and in n015 for the treated group using MRIcro
software. OxAc-treated rats show significantly reduced tumor growth
compared to the control group. *p<0.01 (repeated measures ANOVA
test)
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an effective one [22], we added hGOT to the treatment in
order to elevate the blood GOT levels and possibly improve
the effectiveness of oral OxAc for the scavenging of blood
Glu. As temozolomide (TMZ) is a standard treatment of
glioma, we also determined the anti-tumor effects of
OxAc/hGOT, TMZ and their combination. Tumor size was
monitored in the orthotopic nude mice glioma model after
14 days of treatment i.e. 1 week post tumor implantation.
The mean tumor volumes ± SD were 61±10 mm3, 47±
9 mm3 , 3.5±0.5 and 1.5±0.6 mm3 for the NaCl-treated,
OxAc/hGOT, TMZ and TMZ/OxAc/hGOT groups respec-
tively (Fig. 2).
Histology of the U87 MG glioma in nude mice
To characterize the U87 MG tumor in vivo, in addition to
the tumor volume monitoring, we performed standard
immunohistological staining focusing first on the tumor
center:
1) H&E staining shows that in NaCl-treated mice tumors
show high nuclear pleomorphism and nuclear density (mean
nuclear density: 29±1.6). These characteristics are signifi-
cantly less pronounced in the OxAc/hGOT-treated group
(24.9±2.4), in the TMZ group (19.2±3.7) and in the TMZ/
OxAc/hGOT combination group (7.3±0.4; p<0.001 with
respect to the TMZ-treated group. (Fig. 3a left panel and b).
2) The PCNA data show a significant reduction in DNA
synthesis i.e. in tumor cells proliferation, in all treated
groups versus control (% PCNA positive cells: NaCl: 80.2
±5.8; OxAc/hGOT: 65.7±3.6; TMZ: 43.1±4.1 and TMZ/
OxAc/hGOT: 27.4±5.8; (Fig. 3a middle panel and c). Thus,
the most significantly proliferative reduction was shown in
the TMZ/OxAc/hGOT combination treated group.
3) We used the Aurora A staining as a marker for grading
the glioma tumor. Aurora A, which is also known as serine/
threonine kinase 15 (STK15), is a key regulatory protein
controlling centrosome maturation, spindle assembly, and
chromosome segregation [30]. The presence of high Aurora
A expression levels were shown to correspond with nuclear
and centrosomal abnormalities in high-grade gliomas [31].
In the current study, reliable quantification of the Aurora A
staining was very hard to obtain due to very significant
morphological differences between the groups, which
reflected in high background for the staining. However, it
is quite obvious that there is a trend to lower tumor grade in
the treated groups with almost no positive staining observed
in the TMZ/OxAc/hGOT combination group (Fig. 3a right
panel, small dark brown spots indicate positive staining).
Analysis of the tumor invasiveness using H&E immu-
nostaining shows a significant tumor cell infiltration into the
brain parenchyma around the borders of the tumor in the
control group and in the OxAc/hGOT and TMZ-treated
groups (see arrows in Fig. 4 left panel). This was however
absent in the TMZ/OxAc/hGOT-treated group probably as
the result of the conspicuous astrocytic scar revealed by
GFAP immunostaining (Fig. 4, right panel, see arrowheads).
One can assume that the astrocytes surrounding the borders
of the tumor prevent the tumor growth and invasiveness
(number of astrocytes/area: 191±33; p<0.001, One-way
ANOVA+ Newman-Keuls test). This was not observed in
all other treated animals (124±3, 110±3 and 93±2 for TMZ,
OxAc/hGOT and saline groups, respectively).
Increased survival of CD1 nude mice treated with blood
glutamate scavengers with or without TMZ
A survival study was conducted in separate groups of mice
(Fig. 5). The median survival time in the vehicle (DMSO/
Fig. 2 Tumor growth over 21 days in CD1 nude mice. U87 GM
bearing CD1 nude mice were treated on day 7 with OxAc+hGOT,
TMZ, OxAc+ hGOT +TMZ combined treatment, and control. *p<
0.05; ***p<0.001 (one-way ANOVA with Newman-Keuls post test,
n04) versus control group treated with 0.3 M NaCl
Invest New Drugs (2012) 30:2226–2235 2231
saline)-treated animals was 32 days (n013), 42 days in the
OxAc/hGOT-treated animals (n013), 46 days in the TMZ-
treated animals (n013) and 76 days in the TMZ/OxAc/
hGOT-treated animals (n013). One of the TMZ-treated
Fig. 3 Morphology of tumors
derived from U87 glioma cell
line A. Immunohistochemistry
for H&E, PCNA and Aurora A.
Data are representative of
four mice per group. B.
Quantification of tumor cell
nuclear density (H&E staining);
*p<0.05, **p<0.001 vs.
control group, ***p<0.001 vs.
all other groups (one-way
ANOVA+ Newman-Keuls test,
n04. C. Quantification of the
PCNA positive tumor cell
nuclei staining; one-way
ANOVA revealed significant
differences between all groups
(p<0.001). Data presented
as mean values ± SD
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mouse and four of the combination treatment mice continue
to survive >115 days after tumor implantation. All the
experimental animals were treated until death or until they
were sacrificed. These mice were sacrificed at day 117 and
their brains were analyzed for the presence of tumor cells.
No tumor cells were found (data not shown). The survival of
mice in the treated groups vs. control was prolonged by
137%, 144% and 237% for the OxAc/hGOT, TMZ and
TMZ/OxAc/hGOT combination treatment groups respec-
tively (p<0.0001), exhibiting again the advantage of the
combination treatment on the other groups.
Discussion
Treatment of primary central nervous system tumors such as
gliomas includes surgery, radiation and chemotherapy with
agents such as TMZ, BCNU or 1-(2-chloroethyl)-3-cyclo-
hexyl-L-nitrosourea combined with vincristine [32]. Unfor-
tunately, even the combined modality therapy yields only
2% to 5% five-year survival rates, and poor treatment re-
sponse. The dismal prognosis is due to postsurgery recur-
rences arising from escaped invasive tumor cells.
Fig. 4 Morphological evidence of the tumor invasiveness derived
from U87 glioma cell line. a. Representative example of immunohis-
tochemistry staining for H&E and GFAP. Staining by H&E showing
infiltration of the brain parenchyma by tumor cells detached from the
main tumor mass, arrows indicate the infiltrative cells (left column).
Staining for GFAP showing the astrocytes cells around the tumor
borders, arrowheads indicate the GFAP positive astrocytes (right col-
umn) b. Quantification of the number of astrocytes as indicated by
positive GFAP staining,; ***p<0.001 vs. all other groups, One-way
ANOVA+ Newman-Keuls test, n04
R
Fig. 5 Survival rate in CD1 nude mice-bearing intracranial U87 MG
cells. Kaplan-Meier survival of CD1 nude mice treated with 0.3 M
NaCl 50 ml/day (n013), OxAc 2.14 mg/kg/day/hGOT 2.14 mg/kg on
the first day followed by a maintenance dose of 0. 214 mg hGOT/kg/
day (n013), TMZ 5 mg/kg for 4 days (n013) and a combined TMZ/
OxAc/hGOT treatment with the same doses as the rest groups (n013).
Animals were monitored up to 115 days after the tumor cell implanta-
tion. P-Values obtained using a Long-rank test show P<0.0001
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This manuscript describes for the first time the ability of
blood Glu scavengers to enhance the treatment at gliomas.
This ability stems from the fact that excess Glu in the
peritumoral space of gliomas plays a crucial role in glioma
invasiveness. Glu released via the Glu-Cystine exchanger
kills neighboring neurons and allows the tumor to occupy an
ever increasing space within the brain [2–4]. Our results
demonstrate that treatment with blood Glu scavengers clear-
ly contributes to the inhibition of the glioma invasiveness as
well as to the survival of the treated animals.
In the rat model of C6 glioma, animals treated by OxAc
show a significantly reduced tumor growth compared to the
control group (Fig. 1). To exclude the possibility of a direct
toxic effect of the OxAc treatment on glioma cells, a 3-(4,5-
dimethyltiazol-2yl)-2,5-phenyl-2H-tetrazolium bromide
(MTT) assay was performed on C6 cells exposed in-vitro
to OxAc (3 μM–0.3 μM) for 24 h and no effect was found
(data not shown). Considering our previous [4, 19–21] and
current results using blood Glutamate scavenging in several
animal models we suggest that the therapeutic effects of
OxAc on glioma growth and invasiveness in vivo are due
primarily to the scavenging effect of OxAc blood Glu. In the
case of glioma, our results strengthen the concept that OxAc
caused in increased efflux of peritumor Glu into the blood,
slowing down the ability of the tumor to create the space for
its expansion.
Having demonstrated the in vivo effectiveness of OxAc
to decrease rat glioma growth, we investigated the effects of
OxAc/hGOT alone and/or with TMZ treatment on human
glioma cell line implanted in nude mice. The hGOT was
added to the treatment in order to increase the blood GOT
levels and possibly improve the efficiency of the oral OxAc
for the scavenging of blood Glu. We showed that the com-
bination treatment had an improved effect on tumor growth
inhibition compared to TMZ alone (Fig. 2). The OxAc/
hGOT treatment had a statistically significant effect on
tumor growth, but less impressive than TMZ alone or the
combination treatment. In spite of the statistically insignif-
icant difference in tumor volume between TMZ and OxAc/
hGOT/TMZ groups there is a clear trend of improvement
after the combination treatment. Using a larger number of
animals, would most likely have made it statistically signif-
icant. However, the peripheral administration of OxAc/
hGOT contributed in a very significant way to the survival
of TMZ-treated mice (Fig. 5). The most impressive effect on
survival duration was demonstrated b they combination
treatment.
In a similar way with what was observed with C6 cells,
the U87 cells viability was assessed in-vitro after 24 h
exposure to OxAc (3 μM–0.3 μM) and no effect was found
(data not shown).All immunostaining methods we used
confirm the fact that the U87 MG cells in the NaCl-treated
Nude mice show both proliferation and invasiveness.
Staining with H&E showed infiltration of the brain paren-
chyma by cells detached from the main tumor mass. This
trend is systematically reduced in all mice treated with a
blood Glu scavenger (Fig. 4). The most interesting results
were obtained by GFAP staining that showed the remark-
able recruitment of astrocytes around the borders of the
tumor in the combination treated group only. This is the
first time that this phenomenon was observed. As already
discussed above, excessive amounts of Glu can cause exci-
totoxicity and hence Glu release from gliomas may similarly
exert peritumoral excitotoxicity. Astrocytes are typically
resistant to even millimolar concentrations of Glu [33]. As
it pertains to peritumoral astrocytes, their response to excess
Glu is not well understood. Astrocytes typically respond to
neuronally released Glu by the rapid uptake into the cyto-
plasm using the EAAT1 and EAAT2 transporters. It is clear,
however, that the Glu release from the tumor must over-
whelm the astrocytic capacity to sequester Glu and maintain
proper Glu homeostasis. The space occupied by expanding
tumors is devoid of neurons and astrocytes alike. Low-grade
glioma contain a lower density of tumor cells intermixed
with normal brain, and as these tumors progress to higher
grade, thus astrocytes must be killed by the expanding
tumor [1]. Indeed, we show that no GFAP positive astro-
cytes are observed in the control group, as well as in OxAc/
GOT or TMZ treated groups (Fig. 4). This strongly supports
our histological observations showing a clear trend of blood
Glu scavengers to reduce the glioma grade (Fig. 3). It is
important to emphasize that despite the significant reduction
of tumor volume and extension survival of mice treated by
TMZ alone, addition of the glutamate scavengers resulted in
a significant improvement in all parameters.
TMZ has received much attention in the last 10 years and
become a current standard chemotherapy treatment of ma-
lignant gliomas, but patient’s prognosis remains unsatisfac-
tory. The limited efficacy of the chemotherapy can be
attributed to both inherent and acquired tumor drug resis-
tance [34, 35]. Thus, there is a need for improving the
current therapeutic approach.
Conclusions
We have shown that the in vivo periodic administration of
blood Glu scavengers is highly effective in reducing the
proliferation and invasiveness of both rat C6 glioma cells
and human U87 MG cells in rat and mice glioma model
systems. It is clear that a treatment of such multifactorial
disease like glioma ought to be a complex therapy. As we
demonstrated in this study, the blood glutamate scavenging
treatment could be a good candidate in combination with
TMZ or as an alternative treatment to the patients that do not
respond to TMZ. This is the first time that this approach is
2234 Invest New Drugs (2012) 30:2226–2235
used and it appears that it may be of high clinical signifi-
cance for the future treatment of gliomas.
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